STING agonist promotes CAR T cell trafficking and persistence in breast cancer

CAR T cell therapy remains suboptimal for the treatment of solid tumors. Xu et al. demonstrate that CAR T cell migration and persistence in locally advanced breast cancer are enhanced by coadministration of CAR T cells with STING agonists.

[1]  Z. Modrušan,et al.  CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity , 2019, Science Translational Medicine.

[2]  Jing Wang,et al.  Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. , 2019, Cancer discovery.

[3]  Aaron J Johnson,et al.  GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. , 2019, Blood.

[4]  K. Kinzler,et al.  Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome , 2018, Nature.

[5]  S. Sidhu,et al.  Humanized Mice for the Study of Immuno-Oncology. , 2018, Trends in immunology.

[6]  D. Torigian,et al.  Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. , 2018, Gastroenterology.

[7]  Jian Ma,et al.  S100A8/A9 in Inflammation , 2018, Front. Immunol..

[8]  M. Sadelain,et al.  CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.

[9]  C. Doglioni,et al.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.

[10]  K. Tamada,et al.  IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor , 2018, Nature Biotechnology.

[11]  J. Utikal,et al.  Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression , 2018, Front. Immunol..

[12]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[13]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[14]  A. DeMichele,et al.  Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer , 2017, Cancer Immunology Research.

[15]  S. Akira,et al.  Antitumor effect of Batf2 through IL-12 p40 up-regulation in tumor-associated macrophages , 2017, Proceedings of the National Academy of Sciences.

[16]  Robert Damoiseaux,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.

[17]  S. Albelda,et al.  CAR T Cell Therapy for Solid Tumors. , 2017, Annual review of medicine.

[18]  C. Halin,et al.  T Cell Trafficking through Lymphatic Vessels , 2016, Front. Immunol..

[19]  D. Tscharke,et al.  Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting , 2016, Clinical Cancer Research.

[20]  T. Gajewski,et al.  The host STING pathway at the interface of cancer and immunity. , 2016, The Journal of clinical investigation.

[21]  R. DeMatteo,et al.  Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T , 2015, Cancer Immunology, Immunotherapy.

[22]  Eugene S. Kim,et al.  Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes , 2015, Nature Medicine.

[23]  Ying Wang,et al.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.

[24]  Jing Sun,et al.  Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor , 2011, Clinical Cancer Research.

[25]  M. Veldhoen,et al.  Fate mapping of interleukin 17-producing T cells in inflammatory responses , 2011, Nature Immunology.

[26]  S. Rosenberg,et al.  Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. , 2010, The Journal of clinical investigation.

[27]  C. June,et al.  The Inducible Costimulator (ICOS) Is Critical for the Development of Human TH17 Cells , 2010, Science Translational Medicine.

[28]  F. Powrie,et al.  Innate lymphoid cells drive IL-23 dependent innate intestinal pathology , 2010, Nature.

[29]  W. Chazin,et al.  S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3 , 2010, Cell Research.

[30]  S. Rosenberg,et al.  Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. , 2008, Blood.

[31]  E. Jaffee,et al.  HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. , 2000, Cancer research.

[32]  Z. Eshhar,et al.  Endowing T cells with antibody specificity using chimeric T cell receptors , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  Z. Eshhar,et al.  Functional assembly of chimeric T-cell receptor chains. , 1992, International journal of cancer. Supplement = Journal international du cancer. Supplement.